Literature DB >> 30548019

Economic Impact of HIV in the Highly Active Antiretroviral Therapy Era - Reflections Looking Forward.

Juan Oliva-Moreno1, Marta Trapero-Bertran2.   

Abstract

The main data on HIV in high-income countries from the standpoint of health economics are updated and discussed. Specifically, issues surrounding the economic impact of HIV are addressed for health care and occupational perspectives. We review the main epidemiological data on the prevalence of disease and foreseeable changes in patterns within the coming years. Recent research on health care costs of HIV/AIDS and the occupational situation of HIV+ people are discussed. In high-income countries, there is an incipient change in trends that indicate that an increasing percentage of the intermediate-age HIV+ population will age prematurely, presenting more frequently comorbidities and becoming more exposed to frailty situations. Accordingly, health-care systems should have to plan their resources to accommodate new determinants of healthcare costs in the HIV+ population. On the occupational side, the decreased life expectancy of HIV+ persons, coupled with more severe health issues, on average may prompt early -retirement of this population from the labor market. Copyright:
© 2018 Permanyer.

Entities:  

Keywords:  Aging; Comorbidity; Economic impact; HIV; Health care cost; Labor force participation rate

Mesh:

Year:  2018        PMID: 30548019     DOI: 10.24875/AIDSRev.M17000011

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  6 in total

1.  Clinical Oral Condition Analysis and the Influence of Highly Active Antiretroviral Therapy on Human Salivary Microbial Community Diversity in HIV-Infected/AIDS Patients.

Authors:  Peilin Cao; Yifan Zhang; Guangyan Dong; Hongkun Wu; Yuxiang Yang; Yi Liu
Journal:  Front Cell Infect Microbiol       Date:  2022-06-29       Impact factor: 6.073

2.  The employment situation of people living with HIV: a closer look at the effects of the 2008 economic crisis.

Authors:  Beatriz Rodríguez-Sánchez; Luz María Peña-Longobardo; Juan Oliva-Moreno
Journal:  Eur J Health Econ       Date:  2021-09-03

Review 3.  CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy.

Authors:  Fedora Grande; Maria Antonietta Occhiuzzi; Bruno Rizzuti; Giuseppina Ioele; Michele De Luca; Paola Tucci; Valentina Svicher; Stefano Aquaro; Antonio Garofalo
Journal:  Molecules       Date:  2019-02-02       Impact factor: 4.411

4.  Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain.

Authors:  Vicente Estrada; Miguel Górgolas; José A Peña; Elena Tortajada; Antonio Castro; María Presa; Itziar Oyagüez
Journal:  Pharmacoecon Open       Date:  2022-02-05

5.  Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore-based virtual screening approach.

Authors:  Muhammad Usman Mirza; Atefeh Saadabadi; Michiel Vanmeert; Outi M H Salo-Ahen; Iskandar Abdullah; Sandra Claes; Steven De Jonghe; Dominique Schols; Sarfraz Ahmad; Matheus Froeyen
Journal:  Eur J Pharm Sci       Date:  2020-09-02       Impact factor: 4.384

6.  The Utilisation of Payment Models Across the HIV Continuum of Care: Systematic Review of Evidence.

Authors:  Tiago Rua; Daniela Brandão; Vanessa Nicolau; Ana Escoval
Journal:  AIDS Behav       Date:  2021-06-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.